Yellow Fever Vaccination and Increased Relapse Rate in Travelers with Multiple Sclerosis
Arch Neurol 68:1267-1271, Farez, M.F. and Correale, J., 2011
Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
NEJM 365:1293-1303, OConnor, P.,et al, 2011
Acute Myeloid Leukemia in Italian Patients with Multiple Sclerosis Treated with Mitoxantrone
Neurol 77:1887-1895, Martinelli, V.,et al, 2011
Multiple Sclerosis-Quenching the Flames of Inflammation
Lancet 378:1759-1760, , 2011
A Strange Case of Waitress Headache
Lancet 378:1824, Libera, D.D.,et al, 2011
Cost-effectiveness of disease-modifying therapy for multiple sclerosis
Neurol 77:355-363, Noyes, K.,et al, 2011
Improved Late Survival and Disability After Stroke With Therapeutic Anticoagulation for Atrial Fibrillation
Stroke 42:2503-2508, Hannon, N.,et al, 2011
Azathioprine
Neurol 77:659-666, Costanzi, C.,et al, 2011
Reversible Cerebral Vasoconstruction Syndromes
Arch Neurol 68:1005-1012,976, Singhal, A.B.,et al, 2011
N-methyl-D-aspartate Receptor Autoimmune Encephalitis Presenting With Opsoclonus-Myoclonus
Arch Neurol 68:1069-1072, Smith, J.H.,et al, 2011
Optic Neuritis: Prognosis and Treatment
UpToDate, Jan, Osborne, B.,et al, 2011
Clinical and Functional Outcome and Factors Predicting Prognosis in Osmotic Demyelination Syndrome (Central Pontine and/or Extrapontine Myelinolysis) in 25 Patients
JNNP 82:326-331, Kallakatta,R.N.,et al, 2011
Prior Suggestive Symptoms in One-Third of Patients Consulting for a "First" Demyelinating Event
JNNP 82:323-325, Gout,O.,et al, 2011
Asymptomatic Spinal Cord Lesions Predict Disease Progression in Radiologically Isolated Syndrome
Neurol 76:686-692, 680, Okuda,D.T.,et al, 2011
Immune Reconstitution Inflammatory Syndrome in Patients With Multiple Sclerosis Following Cessation of Natalizumab Therapy
Arch Neurol 68:186-191, Miravalle,A.,et al, 2011
Phase III Dose-Comparison Study of Glatiramer Acetate for Multiple Sclerosis
Ann Neurol 69:75-82, Comi,G.,et al, 2011
When A Brain Lesion Necessitates Chest CT
Conn Med 75:143-146, Finelli,P.F., 2011
Evidence-Based Guideline Update: Plasmapheresis in Neurologic Disorders: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 76:294-300, Cortese,I.,et al, 2011
Diagnostic Criteria for Multiple Sclerosis: 2010 Revisions to the McDonald Criteria
Ann Neurol 69:292-302, 234, Polman,C.H.,et al, 2011
Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy
Neurol 76:1697-1704, Vermersch,P.,et al, 2011
Mechanisms of Fingolimods Efficacy and Adverse Effects in Multiple Sclerosis
Ann Neurol 69:759-777, Cohen, J.A. & Chun, J., 2011
Pediatric Neurological Complications of 2009 Pandemic Influenza A (H1N1)
Arch Neurol 68:455-462, Kedia, S.,et al, 2011
Efficacy and Safety of Mitoxantrone in Patients with Highly Relapsing Neuromyelitis Optica
Arch Neurol 68:473-479, Kim, S.H.,et al, 2011
Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis
Neurol 76:1858-1865, OConnor, P.W.,et al, 2011
Cardiac abnormalities in a follow-up study on carriers of Duchenne and Becker muscular dystrophy
Neurol 77:62-66, Schade van Westrum, S.M.,et al, 2011
Rhombencephalitis A Series of 97 Patients
Medicine 90:256-261, Moragas, M.,et al, 2011
Presentation, Diagnosis, Pathophysiology, and Treatment of the Neurological Features of Sturge-Weber Syndrome
The Neurologist 17:179-184, Comi, A.M., 2011
Primary Central Nervous System Lymphoma in a Patient Treated with Natalizumab
Ann Neurol 69:1060-1062, Phan-Ba, R.,et al, 2011
Paraneoplastic isolated myelopathy Clinical course and neuroimaging clues
Neurol 76:2089-2095, Flanagan, E.P.,et al, 2011
Predicting motor outcome and death in term hypoxic-ischemic encephalopathy
Neurol 76:2055-2061, Martinez-Biarge, M.,et al, 2011
Sustained motion perception deficit following optic neuritis Behavioral and cortical evidence
Neurol 76:2103-2111, Raz, N.,et al, 2011
Disability, distress and unemployment in neurology outpatients with symptoms unexplained by organic disease
JNNP 82:810-813, 710, Carson, A.,et al, 2011
Demographic and Clinical Characteristics of Malignant Multiple Sclerosis
Neurol 76:1996-2001, Gholipour, T.,et al, 2011
MRI Only Conversion to Multiple Sclerosis Following a Clinically Isolated Syndrome
JNNP 82:176-179, Chard,D.T.,et al, 2011
CSF Complements Serum for Evaluating Paraneoplastic Antibodies and NMO-IgG
Neurol 76:1108-1110, McKeon,A.,et al, 2011
A Clinical Prediction Rule for Ambulation Outcomes After Traumatic Spinal Cord Injury: A Longitudinal Cohort Study
Lancet 377:1004-1010, 972, van Middendorp,J.J,et al, 2011
Evidence for Acute Neurotoxicity After Chemotherapy
Ann Neurol 68:806-815, Petzold,A.,et al, 2010
Dysexecutive Syndrome: Diagnostic Criteria and Validation Study
Ann Neurol 68:855-864, Godefroy,O.,et al, 2010
Tourettes Syndrome
NEJM 363:2332-2338, Kurlan,R., 2010
Brainstem Lesion in Clinically Isolated Syndromes
Neurol 75:1933-1938, Tintore,M.,et al, 2010
Pregnancy and Fetal Outcomes After Interferon-b Exposure in Multiple Sclerosis
Neurol 75:1794-1802, Amato,M.P.,et al, 2010
Successful Management of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy and Immune Reconstitution Syndrome in a Patient With Multiple Sclerosis
Arch Neurol 67:1391-1394, Schr�der,A.,et al, 2010
JC Virus Infection of the Brain
AJNR 31:1564-1576, Bag,A.K.,et al, 2010
Long-Term Outcome of Thalamic Deep Brain Stimulation in Two Patients With Tourette Syndrome
JNNP 81:1068-1072, Achermans,L.,et al, 2010
Neuromyelitis Optica Treatment: Analysis of 36 Patients
Arch Neurol 67:1131-1136, Bichuetti,D.B.,et al, 2010
Safety and Efficacy of Natalizumab in Children With Multiple Sclerosis
Neurol 75:912-917, Ghezzi,A.,et al, 2010
Progressive Multifocal Leukoencephalopathy: Can We Reduce Risk in Patients Receiving Biological Immunomodulatory Therapies?
Ann Neurol 68:271-274, Tyler,K., 2010
Severe Cutaneous Candida Infection During Natalizumab Therapy in Multiple Sclerosis
Neurol 74:521-523, Gutwinski,S.,et al, 2010
Robot-Assisted Therapy for Long-Term Upper-Limb Impairment After Stroke
NEJM 362:1772-1783, 1827, Lo,A.C., et al, 2010
Antibodies to Glutamic Acid Decarboxylase Define a Form of Limbic Encephalitis
Ann Neurol 67:470-478, Malter,M.P., et al, 2010